US Patent

US10028920 — Methods for treating occular irritation involving tearing by administering modulators of TRPM8

Method of Use · Assigned to Consejo Superior de Investigaciones Cientificas CSIC · Expires 2031-09-08 · 5y remaining

Vulnerability score 64/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods for treating ocular irritation involving tearing by administering modulators of the TRPM8 receptor.

USPTO Abstract

The invention relates to therapeutic compositions for the treatment of dry eye, more specifically to compositions comprising a TRPM8 receptor agonist ligand. Furthermore, the invention relates to therapeutic compositions for the treatment of epiphora, more specifically to compositions comprising a TRPM8 receptor antagonist.

Drugs covered by this patent

Tryptyr (ACOLTREMON) · Alcon Labs Inc

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1900`	—	Tryptyr

Patent Metadata

Patent number: US10028920
Jurisdiction: US
Classification: Method of Use
Expires: 2031-09-08
Drug substance claim: No
Drug product claim: No
Assignee: Consejo Superior de Investigaciones Cientificas CSIC
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.